Sticky Areas of CPI… And Summit Therapeutics Co-CEOs On New Drug Results 9/11/24

11 Sep 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Episode Notes: CNBC's "Fast Money" - Sticky Areas of CPI… And Summit Therapeutics Co-CEOs On New Drug Results 9/11/24

Episode Overview

  • Host: Melissa Lee
  • Key Topics:
  • August inflation trends and implications for the Federal Reserve.
  • Analysis of CPI components and their impact on the economy, particularly housing.
  • Summit Therapeutics' stock surge following new lung cancer treatment data.
  • Insights from Affirm CEO Max Levchin on consumer finance trends.

Key Takeaways

  1. Inflation Trends and CPI Analysis
  2. Consumer Price Index (CPI):
  3. August inflation at 2.5%, the lowest increase since February 2021.
  4. Key components, particularly housing and auto insurance, remain elevated:
  5. Rent: Up 5%.
  6. Daycare/Preschool: Up 6.2%.
  7. Auto Insurance: Up 16%.
  8. Discussion on the "stickiness" of these elements in inflation figures.
  • Implications for Federal Reserve:
  • Market sentiment shifts towards a likelihood of 25 basis point rate cuts, reducing the probability of a 50 basis point cut.
  • The Fed’s response considered crucial as rents and housing inflation are projected to influence future monetary policy.
  1. Analysis of Housing Market
  2. Steve Leisman (CNBC senior economics reporter) discusses:
  3. The disconnect between CPI and private sector data indicating slower housing cost increases.
  4. Extended time forecasted for CPI to reflect changes in housing prices.
  5. Market speculation on the Fed’s potential rate adjustments based on CPI readings.
  • Consumer Behavior:
  • Persistent high housing costs affect consumer sentiment despite overall economic improvement.
  1. Summit Therapeutics' Lung Cancer Drug Results
  2. Company Performance:
  3. Stock increased nearly 100% in response to promising lung cancer drug trial results.
  4. Co-CEOs Bob Duggan and Dr. McKee Zangana discuss the drug's competitive position against established treatments like Merck's Keytruda.
  5. Numerous phase trials planned to explore the drug's effectiveness across various cancer types.
  • Market Impact:
  • The drug is positioned as a potential "Keytruda killer," with expectations for significant market penetration.
  1. Insights from Max Levchin, Affirm CEO
  2. Consumer Credit Trends:
  3. Affirm experiencing an improvement in borrower performance, contrasting with reports of deterioration from other financial institutions.
  4. Levchin emphasizes the company's risk management strategies and robust consumer demand.
  • Market Position:
  • Affirm’s partnerships, including a future collaboration with Apple, are poised to enhance growth despite economic headwinds.
  1. Market Reactions and Observations
  2. Market Dynamics:
  3. Discussion of market volatility with significant reversals following inflation reports.
  4. The tech sector, particularly NVIDIA, experienced notable gains post-CPI release.
  5. The podcast also touches on geopolitical factors affecting uranium stocks, influenced by Russian export policies.

Conclusion This episode of CNBC's "Fast Money" provides a comprehensive analysis of inflation trends, housing market challenges, biopharmaceutical advancements, and shifts in consumer finance. The discussions offer valuable insights into the economic landscape, investor sentiment, and the performance of key market players.

Note: For more detailed insights, visit [Fast Money on CNBC](http://fastmoney.cnbc.com).

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Live from the NASDAQ market site in the heart of New York City's Times Square, this is Fast Money. Here's what's on tap tonight. Housing headaches, inflation may be moderating, but one crucial component of CPI remains stubbornly sticky. What it means for the economy if rents and home prices stay high. And scaling the summit, shares of one biotech company have nearly doubled just this week. And it's only Wednesday. We'll talk to the co-CEOs of Summit Therapeutics to get the latest on their lung cancer drug trials. Plus, a read on the consumer from Affirm CEO, Max Levchin, what he's saying from the fintech space and what it could mean for the payment stock.

0:34I'm Melissa Lee. Coming to you live from Studio B at the NASDAQ on the desk tonight, Tim Seymour, Karen Feinerman, Julie Beal in the house, and Guy Adami. And we start off with a major market reversal on Wall Street today. The Dow clawing into the green by the close after falling nearly 750 points at the lows. The S &P up a percent in the big winter. The tech-heavy NASDAQ gaining more than 2 % today, led by some monster gains in NVIDIA. We'll dig into that later on in the show. But all this action coming after this morning's August inflation report. Consumer prices rising 2.5 % from a year ago.

1:04Its smallest increase since February 2021, but several key parts of CPI remain persistently elevated. Rent was up 5 % from a year ago. Daycare and preschool up 6.2%. And auto insurance more than 16 % above year-ago levels. All expenses that are hard, if not impossible, to cut from budgets. For more on the inflation breakdown, let's bring in CNBC senior economics reporter Steve Leisman. It's really no wonder why the consumer doesn't feel so great, even though the economy is largely good. I think that's right. The inflation offsets a lot of the other stuff that's going on. Melissa, this is somewhat hotter than expected CPI, giving markets a choice of whether to fade the number or, of course, to run in fear.

1:45Most have decided to fade it with the understanding that most of the gains came from that stubborn and expectable continued high levels of housing inflation. Take a look here. Shelter rising at 5.2 percent, the broader shelter index on an annual basis. That compares with two and a half overall and three, two for the core, which is pushed up in part by housing and maybe residual seasonality for airline fares. But private sector data from Zillow suggests actual shelter costs rising at a much slower rate. Dana Peterson from the conference board tells me it could take more than a year and a half of which we're sort of into that process a bit already for the private sector data to be picked up in the CPI.

2:22and economists in cities saying, quote, given the slowing in rents and house prices and lack of response of mortgage purchase applications to the drop in mortgage rates, we think the pickup represents volatility around a cooling trend rather than a shift back to faster housing inflation. Markets, to an extent, have embraced this idea of fading it, but they did see today's CPI as a greater indication for 25 rather than a 50 for the Fed to start. They continue to price in very aggressive rate cuts over time, 100 basis points by the end of the year. And now the market's priced for 250 basis points over a full year, bringing the Fed quickly down and even now pricing below neutral, Melissa.

3:03So on the back of the number this morning, Steve, the 50 basis point cut was basically dead according to the probabilities, right? It went down almost zero. So did that shift sort of to within this year but later? Well, just to quote Monty Python, not quite dead yet. We've got a 15 percent probability. But you're right. I just couldn't resist the quote. Sorry, 13 percent probability down from 30 percent. You're right that that what happens is they shift it. Now they're they're debating whether or not the November number is 50. But ultimately, they have that 100 basis points, 4.25 % to 4.5 % by the December meeting is a 100 % probability priced right in right now.

3:48So that's where the market is priced. I think the Fed comes in steps, 25, 50, 25 is the pricing right now. And they've been very consistent about the market pricing anyway. But the Fed has not been. But that 100 basis points this year, what's really interesting to me, I don't know if they have that September 2025 Fed funds contract in the back there. But that's really been aggressive now. It used to be 310, 315. Now it's down to 288, which is a full 250 basis points over a 12-month period. Steve, a couple of these components are sort of intertwined. So rent, we know, is very sticky. But then you lump insurance on top of that.

4:26Landlords need to pay the insurance. They pass it on to their renters. That doesn't seem like it sort of rectifies itself anytime soon. So the stickiness there, it seems like it's going to stay that way for quite some time. I don't think the Fed can combat that. But thoughts on that sort of silo? Yeah, it's a bit of a cycle. You're absolutely right. One thing you can notice, though, Melissa read the 16 percent. Remember, it was 22 percent. So sequentially, it's coming down. The auto insurance thing is reflective of the rise in auto costs. And then that sort of has stepped down a little bit over time here as they play catch up.

5:06The problem is that these insurance contracts, they only renew, what is it, one twelfth of them every month. So you've got to keep renewing it. And, of course, as the price of the auto rises, the price of the repair goes up. So they keep raising it. Eventually, the thinking is you catch up to it, you catch up to the prices. We have seen some attenuation of car inflation. But you're right about the home insurance side of things, which, by the way, is a disaster in several of these disaster areas. That is a completely different topic when it comes to things like home insurance in Iowa or Florida.

5:40Yeah. Steve, it's Karen. Thanks for being on. So do you think that that forward looking that we'll get 100 basis points this year will be is if this comes in the same every month for the next three months? Is that still what you think the market will price in for that? Yeah, I think the first hundred is an easy hundred. I think that the Fed wants to give the economy credit or, put another way, bring the rate down to a place that's more commensurate with the current rate of inflation. And if you think about it, the 538 was set back when inflation was quite a bit higher and to address an issue that is no longer out there, which is that we weren't close to the target.

6:26We're close to the target now. So you can get 100. That next 150 and getting back to neutral, I don't know. I think what you're saying is if you stay in this two and a half to three percent range. By the way, you all know this. If you don't, I just want to make sure you do that. The CPI runs a half a point or more hotter than the PCE, which is what the Fed bases inflation on. So we're darn close to the target here. You don't need such a restrictive policy. Whether you need a somewhat restrictive policy is exactly the answer that you just gave us, Karen, which is going to depend upon whether or not we start trending back down to the target range.

7:05Steve, great to see you. Thanks so much. Pleasure. Steve Leisman, the reaction to the markets fascinating today because immediately it was like, this is terrible. Right. We sold off. And then a huge reversal to finish at the highs. Especially in the leadership parts of the market that at least those that are tracking the market itself wanted to see. You saw semiconductors from 10.36 a.m. go up 6.2 percent to the close. I mean, what was that? Some of it is, I think, dip buying and dynamics, where if you look at some of the biggest stocks in the market, NVIDIA was not surprising, therefore up over 8 percent.

7:38You know, you have a case where I think there was some people, there were people out there with shopping lists. I also just think that yesterday was a day where we had this dynamic where there was kind of this credit overhang coming from the Sparkleys conference, the J.P. Morgan comments, the ally financial delinquencies that suddenly look awful after only a few weeks ago weren't so bad. And I think that played into today. And you get a hotter CPI, at least on its core. And I think that's kind of what took the market. It's also interesting that commodity prices in that core CPI were lower for the fifth time in six months.

8:11And I'll repeat, I think bonds, so treasuries and commodities tell us we have a hard landing coming, whereas credit and equities tell us game on. And I think, too, it's important to keep in mind that there is a big difference between the CPI and the PCE, particularly on the shelter metric. Like the way that they collect shelter is through owner equivalent rent, which is literally calling people up and being like, hey, you own your house. What if you rented it? How much do you think it would be? Why don't they just ask me if I love my kids? It's like it's a really silly question to be asking people.

8:41And it's a strange metric. And it's kind of an anachronism. The Zillow data is much clearer that for sure we see a lot of softness and shelter. And so I think a lot of investors have digested that. I think if we had seen CPI increasing on other metrics like food, that would have been more concerning. But I'd seen 150 point, 150 handle reversal from high to low. I'd make a big deal of it. So I have to make a big deal of it today. It's a huge move. I mean, it's extraordinary, actually, but we should bring up, I mean, look at what dollar yen did today. Tim was talking about it as well. Traded down to 140.70, which is the lowest we've seen in quite some time.

9:19Much lower in terms of the dollar than we saw on August 5th, only to see it reverse hard. So I think some of the reversal today in the equity market might have been on the back of that. The point being, this dollar yen trade, this unwind of the carry trade is not over. So more volatility ahead, I think. I sort of thought that a lot of what happened early in the market was this sort of knee-jerk response to the idea of Harris doing better and the idea of a Democratic presidency being less favorable for the market. I felt like that was a pretty big driver. I don't know why that would have been the same at 10 a.m.

9:59as it would be at 3 a.m., but I think that was just sort of the knee-jerk reaction. I'm not sure. I was in the 50 basis point camp. I had left 25 basis point camp. To be in the 50 camp, this was just a little too hot for that. And I think the—so— So you drove back to 25. Yeah. How does it feel over there? Yeah. I liked it. Not that different. Not wildly. Halfway there. Yeah, not wildly. You might go back, though. You might. Yeah. Who knows? All right. For more on CPI and that housing number, let's bring in Intercontinental Exchange's Andy Walden. He's the VP of Research and Analysis. Andy, great to have you with us.

10:33So a lot of the—you know, going into this number, there's so much expectation. expectation that the shelter component would come down based on the private sector surveys that we had seen. If it was so well known that it takes a year for that to read and go into the data, why wasn't it expected that they would not come down? It's a good question. I mean, you're right. If you look at any of these other numbers out there, you look at the true rent numbers, you look at the latest ICE home price index, it says home prices have been cooling for the last five months, and we saw our coolest reading in the last 12 months.

11:02And so there, as you've mentioned already, There's some walkiness in that number in the way that it's calculated. Certainly a lagging indicator in terms of what's truly going on out there in the market. Andy, if I look at housing overall and I hear some of the comments from what we've heard on the credit side from the consumer over the last couple of days, we're talking about auto loans, we're talking about student loan delinquencies. Can you just give me some sense how this is playing? And we've heard certainly from the builders themselves. We know where supply dynamics are for the market, so we know there should be a bid to the housing market.

11:30But we have not really gotten to the side of the strength of the consumer and the housing balance sheet. Yeah. When you look at delinquency rates, they're still historically very low. They're a full percentage point below where they were in the early 2000s. They're a full percentage point below where they were kind of leading up to the COVID pandemic. In recent months, we've hit a nearly 20-year low in terms of seriously delinquent mortgages and foreclosure activity is through the floor right now. And so really, when you look across the board, you're not seeing a whole lot of concern. Now, the one area that we do have our eyes on are more recently originated loans, where we know that folks were stretched from an affordability standpoint, debt to income ratios were higher.

12:08We're also seeing a modest rise among some of those FHA and VA type mortgages that are more entry level buyers. We're certainly seeing some gradual rise in delinquency rates there that we expect to be kind of the early indicator for the market this time around. But broadly speaking, you're still seeing very low delinquency rates in that mortgage space. How do you think through the drop that we've seen in mortgage rates? I mean, mortgage rates now are at their lowest, I think, since February of 2023, given the strange sort of, you know, supply demand dynamic that we have here. A lower mortgage rate doesn't necessarily mean it.

12:39I mean, how do you how do you sort of factor that into housing prices? Yeah, you're absolutely right. And if you look at the mortgage rate yesterday, it was six point two percent compared to according to our in-house ICE data there. That's down a half a percent from where we were at the end of July, down a full percent from where we peaked out in May. So it's certainly moving the needle from an affordability standpoint. And anytime we've seen rates fall like that, you've seen a corresponding return in demand. And so I think that's the big question, Mark, from a home price perspective. We've been in a cooling cycle this year.

13:09The question is, does that speed things back up? And when you look at purchase loan applications, when you look at purchase rate locks, we've seen four of our strongest weeks of this year here over the last few weeks. But it hasn't been as strong of a reaction as we saw even early this year when rates fell to a higher level or more specifically in early 2023 when rates fell below where they are right now. We're not seeing as strong of a response. And so we may see some firming of prices. I'll have my eyes on inventory data when it comes in for September to see if it starts to buy down inventory levels.

13:40But I wouldn't expect as strong of a reaction as we saw in 2023 when rates fell and the housing market significantly sped back up. But again, that's to be seen here over the next few weeks and next few months out there in the market. And despite the fact the unemployment rate's gotten up to 4.2 percent, it's still pretty much at historic lows. What is the rate where the housing market starts to take notice? I think you'll gradually see that impact, both mortgage performance, mortgage delinquencies, as well as demand out there in the market. I don't think there's a true trigger point in terms of seeing a cliff there.

14:11But obviously, one of the key components to being able to afford to buy a new home or afford the mortgage on your existing home is having a job, right? So there's this corresponding impact. As unemployment rises, you're going to see both of those metrics impacted. But I don't think there's a cliff point where we get to a certain point and you see a massive incremental impact. Andy, great to see you. Thanks. You bet. Thank you. All right. So the way Andy described the consumer doesn't sound too, too bad in terms of delinquencies not being as high as past peaks. Yeah, I mean, well, I think it was a much more conservative underwriting than we've seen, right, in certainly a couple of cycles.

14:48So there's that, and then there's the really low mortgage, and so the affordability from that vintage, right? But I'm really curious as to when all that locked-up existing home inventory has to hit the market. We know, obviously, much lower rates would make it hit the market because then this cheap mortgage you have, you could get another one to buy another house. But when people need to either age out or have to move or I don't know how long that's going to be. But those loans are probably, what, three or three years old now. They're really cheap ones. I don't know. At least. I mean, right. It has to be three.

15:24Yeah. I don't know when we'll start to see that. It's like all the governments that were out there issuing 50 year paper, you know, 1 percent in emerging markets. I mean, it's pretty crazy to think about how you were able to. But it's also crazy to think about how the Fed has only been issuing short term and not really issuing on the long end to kind of massage what is a really difficult refunding dynamic, by the way. You know, pretty good 10 year auction out there. I just you know, I think it's it's a case where the the consumer I would choose to focus on the credit side of things and I would focus.

15:55I understand, again, back to the home builders. We know that they're in very good shape other than Lenar, who apparently is discounting heavily to clear through inventories. We kind of understand where they've been able to actually hold margins even at higher rates, even while financing some of the underlying purchase. But it's just, you know, if the household balance sheet takes the kind of a turn that we're getting these metrics on, I think that's the issue for the housing market. And, you know, it's not right now. And do not miss CNBC's first ever interview with billionaire investor John Paulson, who famously bet against the U.S.

16:27housing market during the financial crisis. That's Friday, 1115 a.m. Eastern Time, right here on CNBC. Coming up, shares of NVIDIA bouncing back from the recent slump, what CEO Jensen Huang said about spending and chip delays next. Plus, some heavy-hitting new data for Novo Nordisk, the new data on its weight loss pill, and where it puts Novo in the obesity drug wars. Don't go anywhere. Fast Money is back in two. This is Fast Money with Melissa Lee, right here on CNBC.

17:04NVIDIA stock soaring 8 % today for its best day in a month. CEO Jensen Huang speaking at Goldman Sachs' Communicopia conference this morning. He spoke about when the company's new Blackwell chip platform will be rolled out and how AI is helping reduce costs. Seema Modi's got more on what Huang had to say in conversation with Goldman Sachs CEO David Solomon. Seema. Well, Melissa, NVIDIA CEO Jensen Huang said the cost benefits of artificial intelligence will incentivize big tech to continue to spend, adding that hyperscalers can generate$5 in rental revenue for every$1 spent on NVIDIA's infrastructure.

17:37He also reiterated that Blackwell ships out in the fourth quarter and that the market needs to think about Gen.AI not just as a tool, but a skill that expands beyond data centers. So think digital chauffeurs, digital assembly workers. When Solomon asked Wong about Taiwan, though, and the geopolitical risk, the NVIDIA CEO made the point that the company is dependent on Taiwan's semiconductor and credits the Asian manufacturer for its surge in revenue, though said if something were to happen, performance may be impacted.

18:10Maybe we won't be able to get the same level of performance or cost, but we will be able to provide the supply. And so I think in the event anything were to happen, we should be able to pick up and fab it somewhere else. Unclear where else NVIDIA would fab its chips. Taiwan Semi is still behind on getting its Arizona plant up and running in Intel, while developing five plants here in the U.S. is dealing with its own set of issues, Melissa. That's right. Seema, thank you. Seema Modi. Huang also mentioned the competition for the chips out there and how he's got more, quote unquote, emotional customers than before because they're all fighting over these chips, so desperate to get their hands on them.

18:54Julie? I mean, it's like they're so emotional. It's like I love that description. Crying. But it is, right? And I think that's a real reflection. The other thing that I thought was so fascinating that he talked about was, you know, their ability to continue on Moore's Law. We've kind of found the end of Moore's Law. And it's an important fact because so much of what is important about AI is can we get the cost down? And what's unusual about AI, unlike other technologies, is that in order for the models to get better, you actually have to spend more money. And so we're not getting that deflationary tech that we typically get in most tech trends And so that's kind of a critical question that I'm still waiting to understand.

19:33The five to one payout, in other words, for every dollar spending at five back, I mean, that still has to be proven. Yeah. I don't think we're there yet at all, but it's fine that you can say it. But unambiguously, the reversal today on what was very big volume day is a very good thing. You know, we traded back through a moving average, which is encouraging. I mean, it gives you reason to think technically maybe this thing has some further upside over the next week or so. I was just, you know, we were talking about the Oracle call two days ago, which I thought I was surprised NVIDIA had such a muted response to that yesterday because I thought it was wildly bullish.

20:08And I would think this should have been the response. So I do feel like the there's still a big question about the productivity, the return. Right. But I don't think there is a demand question. And I don't think Blackwell being delayed. It's delayed, not denied for that sale. So I think it will happen. So and then just to get into the performance of the group overall today. And if you if you look at the market, the S &P was certainly struggling to hold above that 100 day and was challenging it for the first time, really outside of that August 5th downdraft going all the way back a year. And with the Nasdaq, you were testing actually the 200 day.

20:45Well, in the case of semiconductors, they were essentially looking to bounce and getting a bit of a bounce this morning. Obviously, they did ultimately get the bounce. But the performance of the group is critical. And if you look at where semis have been relative to the market, I mean, they've been making lower lows against the S &P going all the way back to that CPI in July, July 16th, July 17th. What I thought was, again, it was it was a very big moment for the the rates market and what the Fed was going to be doing. It's ironic that that market triggered a downdraft in the high multiple, high tech, high growth trade.

21:17There's a lot more fast money to come. Here's what's coming up next. An easy pill to swallow. Novo Nordisk gaining on its latest weight loss drug data. How it stacks up against the competition and what it means for the obesity drug wars. Next, and sticking in the drug space, one biotech stock surging this week as new lung cancer data beats out a key competitor. The co-CEOs lay out the details and what it means for the company's future. You're watching Fast Money, live from the Nasdaq market side in Times Square. We're back right after this.

21:58Welcome back to Fast Money. Shares of Novo Nord is gaining more than 4 % today on early trial results from its GLP-1 pill. The company presenting phase one trial data at a conference in Madrid saying that patients taking the pill version of amicretin lost up to 13 % of their body weight over 12 weeks. Patients taking the injectable with Govi lost around 6 % over the same period. Side effects are reported to be similar to the injectable versions. The pill has not yet been directly compared to drugs in a lab, and the phase one trial has not yet been peer reviewed. But so far, the indications look promising.

22:30Also, the fact that there is no plateauing towards the end of week 12 indicates that there could be more weight loss even beyond week 12, which would make it even more effective than the current blockbuster they've got in the market. Well, it provides at least some support and reassurance for the competitive nature of this product relative to the peer group. It's interesting. I don't know where Lilly closed, but it was certainly not suffering from the back of this news either. So it really, again, you know, I think it becomes more about the addressable market story. That's where we go with the story.

22:58That's where the analyst community has the ability to slap almost any number they want to. And I think for the next couple of years, those earnings are intact. I think there's going to be plenty of competition. And you would think with this positive data that the competitors or the upstarts, they would trade lower, but they did not trade lower. We had Viking trade higher, and I thought immediately that Viking would be down on the news. No, I think it's just a case of the more that this market can expand and become accessible, and part of that is having it in a pill format makes it much easier for people who are squeamish about having to do auto injectors or going into an office.

Read the full transcript

23:31The minute you lower the barriers to entry and you make it easy to access this, it just expands the whole market. So I think for now we're still in the very early stages of competition, and it really feels like a gold rush. Speaking of squeamish, Francisco Alvarez just hit a three-run bomb. It's now 6-1. Mets, who were getting no hit before, and Guy was giving me heat, are now winning 6-1. Is that relevant? It's not. I think there's some people that have been tense. No, it's relevant because the mood swings that I'm feeling here. The emotions again are the emotions. I was on such a high before the show.

24:04The Mets were getting no-no, now they're up 6-1. And, you know, it's one of those games you're going to look back on, Tim, and say that was a big deal. Yeah. Springboard. Forget the drug business. I think it's important for people to know what's going on. They split us up. They split us up. Yeah. Smile versus not so much. All right. Coming up, Shares of Summit. Speaking of the drug business, Shares of Summit Therapeutics up nearly 100 % this week. The biotech's new lung cancer drug shows huge promise. The co-CEOs will join us next to lay out the findings and how it stacks up against the competition.

24:35And we're going nuclear, uranium jumping as Russia looks to cap exports. What do traders think about the heavy metal moves when Fast Money returns? Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

24:59Welcome back to Fast Money. Stocks bouncing back after an early sell-off, the Dow, which dropped 700 points at its lows of the day. closing the day up more than 120 points. The S &P up more than a percent. Now on a three-day winning streak. And tech leading the charge, the Nasdaq jumping more than 2 percent. Shares of Williams-Sonoma getting a bump up 3 percent. Analysts at Jefferies upgrading the stock to a buy, citing upside in the company's brands and a slight housing recovery. The stock now up 33 percent this year. I guess sales of Dutch Evans are strong. And check out Trump media sinking more than 10 percent today on the back of last night's presidential debate.

25:33now at its lowest level since going public in late March. Now to follow up on a story we brought you on Monday. Summit Therapeutics up a whopping 85 % so far this week. Even with today's 1 % pullback, the huge move follows new data on the company's experimental lung cancer treatment, which beat Merck's Keytruda in a head-to-head trial conducted in China. For more on the path ahead, we're joined by Summit's co-CEOs Bob Duggan and Dr. McKee Zangana. Great to have you both with us. In terms of the stock reaction, it is really because your drug is now being viewed as the Keytruda killer. Can you walk us through, because this trial was specifically for non-small cell lung cancer, what other indications do you think this could be used for?

26:19Maki, I don't know if you want to take that. Thank you very much, Melissa. Actually, as you saw, the clinical development plan of our partner, a case so is over five phase three program in non-small cell lung cancer and multiple phase two program in seven additional therapeutic area. If it's a head and neck, colorectal cancer, breast cancer. So this drug like Keytruda has a lot of potential in multiple therapeutic area beyond non-small cell lung cancer. And in right now we are over 20 clinical trials, over 2000 patients enrolled, and we have our efficacy and safety profile in this drug. So the assumption of the market, Bob, is that it will be, I mean, and McKee addressed this, you know, Keytruda treats at least 18 different kinds of cancer, that this drug will have a similar profile.

27:05And so therefore we'll achieve that sort of level of blockbuster status. Yeah, Melissa, good to be on with you live. I've watched you for many years and have always enjoyed your coverage. That's that's the blueprint. The reason we partnered with Aqueso, a company from China, Big Pharma wouldn't do it. We were excited because we saw the opportunity. We have a good background in China. But the blueprint for where this drug could go is laid out. We have to follow it and beat it. So we went head to head, decisively had a victory. We expect that to continue. And we'll go after a number of therapeutics simultaneously.

27:45So the work is out there. It's not going to be easy, but it's a plan, a program that is pretty clear. The one note of caution regarding the data, McKee, is that the trial was done in China, and there are some differences in the patient populations in China versus the EU and the U.S. in terms of various sensitivities to different VEGF mechanisms. Can you walk us through how you will address that and if that is an area of concern? Because that's what, if you wanted to nitpick, that's what investors are nitpicking. Bob, do you want to answer that? Yeah, Melissa, let me just touch in on that. Both of us have long backgrounds in China, bringing robotics there and Imbruvica there.

28:25We know the population quite well. We are, on our current trial, have two-thirds are China patients, approved by the FDA to have two-thirds. Trials going forward that we've discussed with them, we're looking probably about one-third. Asian population has got to be at least 30 % to 35 % on the entire planet. It would be terrible to leave them out. We feel that it's very adequate. All previous examples of drugs being dosed have worked out quite well. So we see no empirical data that we should do anything other than what we are. We're quite confident that the plan is vetted with the authorities that it should be both in China and in America.

29:06Bob, your stories? Oh, I'm sorry. Please go ahead. I just wanted to say that at the end of the day, we have already, we finished it. We are in the process to finish our phase three, the first one enrollment. And we have a second one already ongoing. And all is a U.S.-European patient as well as Chinese patients. And we are doing our clinical trials in the United States. And we already enrolled patients in the United States and Europe. So at this point, I can say that it's not only Chinese patients. We are in the process to bring it for the rest of the world. Yeah, only would not work, but partial is very workable.

29:45What I was going to say, Bob, quickly is you have a fascinating story. You bought a biotech off the scrap heap. You sold it to AbbVie for, I think,$21 billion. My question is, are we looking at somewhere? Can you go it alone or, you know, is this at some point a takeover candidate? Well, you're an insightful investor, and I'm sure you run a pretty good portfolio yourself. So, you know the parameters. But my competition usually, where's the exit? What is the exit? When is it? That's not my view. My view is how do we impact patient lives, make a significant difference for the better, focus on that, the money will come off the trees.

30:22And that historically has worked, and I'm not changing my approach this late in life. I've got to ask you about the Biosecure Act moving closer to being law, being passed by the House. You both, as you mentioned, have long track records in China. You also have played in the development of Mbruvica, whose critical ingredient is manufactured in China. And I'm wondering what your take is on the Biosecure Act and what the impact would be on pharma and the development of drugs, the cost of drugs as well. Yeah, very, very interesting. This opportunity, when you look at it globally, we are importing product from China.

31:00We have the ability and the capacity and the approval to make it in the U.S., sell it in the U.S. around the world. over 85 percent of the returns and even higher will come back into America as revenue and profit. There'll be employment gained in the United States. This is a wonderful opportunity where China is contributing with us and our citizens will have access to now what is decisively, you know, that we think the best coming drug in non-small cell lung cancer and quite a few others. So we're really happy that they decided to open the door up and that we stepped in and took advantage of it.

31:40Inflation reduction aside, drugs go generic eventually and they're nickel on the dollar. And you and I, our homes never go to a nickel on the dollar. Cars don't go to a nickel on the dollar. Nothing goes to nickel on the dollar except in the capitalistic system run by big pharma. And we're happy to be under that pressure. We think we've got a great opportunity here. And many of our partners in China from Aqueso have American passports. And Aqueso is an owner of the company as well. So we will work our way through and around any acts of Congress. But we know we're in good keeping to capitalism.

32:16We are on the right side of the fence here. And we think eventually the law will regulate in that direction. Aqueso is not mentioned as one of the companies in the Biosecure Act, Bob. But you're talking as if this act would directly impact your ability to actually bring this drug to market. Would it or no? No. No. OK. No, not at all. No impact whatsoever. OK. Glad to get that straight. Thank you both. You make it in America. Yes. Thank you both for joining us, Bob Duggan and McKee Zangana. Thank you so much. Coming up, radioactive trading. What is behind the big move in uranium and related stocks next?

32:49And shares of Affirm still down more than 20 percent this year, even after its recent rally. CEO Max Levchin will join us from Goldman's Communicopia Conference, where he sees his Company's heading next. And a quick programming note, do not miss an interview with Republican VP candidate J.D. Vance. That's tomorrow on Squawk Box, 7.45 a.m. Eastern time, right here on CNBC. Meantime, more Fast Money in 2.

33:17Welcome back to Fast Money. Uranium stocks surging today after Russian President Vladimir Putin asked his government to consider export caps on the heavy metal, as well as nickel and titanium. Back in May, President Biden signed a bill prohibiting Russian uranium imports, which had accounted for 35 percent of all U.S. nuclear fuel imports. U.S. producers like Energy Fuels, Cameco, Uranium Energy, Encore, NextGen, all seeing big gains today. Tim? It's been an unbelievably volatile period, I know, for markets, but certainly in the uranium sector. And I think it's going to continue to be. But these kind of headlines are indicative of the geopolitics and the bid there.

33:52But really, the squeeze bid is part of where this is. And the SqueezeBit exists even without Russia threatening to retaliate on sanctions against them. Good luck. And, you know, that's just the way the world is. I mean, the world is not only doing, I think, to Russia what they should have coming to them, but also what the world is doing is recognizing the importance of nuclear power and enriching on their own and not being reliant anywhere. So we're talking about Germany, which was more or less mothballing. Japan, which obviously had a scare but has completely reversed field. And you get back to this country and you look at major utility suppliers.

34:23There are people that are short. And I think that's part of the story here. So I stay long over long periods of time, but it's not a simple trade. No, I think for long term investors, uranium just makes so much sense. Given all of our ESG targets, it's impossible to make it happen with non-baseload power. So wind and solar, it just cannot do it all the time. What we have with nuclear is the potential for baseload with no carbon emissions. And I think that's why you see, you know, investors like Sam Altman coming in there with their own, you know, nuclear startups. is this recognition that energy demand is going nothing but up.

34:56URA, the uranium ETF is a pretty big sell-off since May. You're actually getting a shot here at decent levels. I think Cameco or Cameco. Cameco. Let's do Cameco. That's what I do, Cameco. That's about 22%. Then the Sprite uranium ETF is about 10%. So that's an interesting way to play it as well. Coming up, Affirm CEO Max Levchin will join us from the Goldman Sachs Communicopia Conference in San Francisco, how the buy-now-pay-later company is positioned and what the future of fintech looks like. More Fast Money into.

35:31Welcome back to Fast Money. A firm share soaring today, climbing back into positive territory for the week. The fintech stock now up more than 20 percent since a blowout earnings report last month. The company has plans to expand further over the next year. Our Kate Rooney is live with CEO Max Levchin from the Goldman Sachs Communicopia Conference in San Francisco. Kate. Hi, Melissa. Thanks so much. And Max, thanks for being here. Great to see you in person. Great to be here. I want to get your take on the consumer. We had some big news yesterday from Ally Financial. The CFO talked about some consumer weakness, said that inflation in particular and the job market is really weighing on consumers.

36:06What are you seeing from a firm's borrowers right now? Now, I have to say we're not seeing that. I think, so not a direct quote, but close to what I read in a transcript was that they noticed a deterioration of consumer credit quality, credit performance over the last few months. we have seen an improvement over the last few months. So our consumer, and we span a fairly large part of the U.S. at this point, is not struggling to pay our bills. There are lots of structural reasons why we're very different. We're unsecured loans, much shorter term, always centered around point of sale. So it's a fairly different type of product.

36:47But apples to apples, we're not seeing it. That's fascinating. Is that true across all income levels for you? Yes. Of our users, yes. Really? Wow. I mean, that's so different from what others in the card space have said. I guess other than Visa, MasterCard, who've also said the consumer's strong, that might surprise a lot of people. So I think structurally, it's always really good to remember we are fundamentally advantaged. Very short term, relatively speaking, every transaction is underwritten separately. Every transaction is priced for the risk it represents in the moment of underwriting. We are compensated for the risk we take.

37:20And as a lender, we do take risk, but we're very good at managing it, and we don't allow it to run away from us ever. And so our results are not an accident. So I want to ask you about the Apple partnership. I know there's things you probably can't talk about, but in terms of expanding the lending base with Apple, I wonder, you know, as you look at credit quality and sign up some of these big partnerships, how are you keeping that in check? Or is it really Apple sort of maybe in some cases being the bad guy and saying, no, you're actually not eligible to pay in four-year for an iPhone? On the Apple thing, super excited to bring it to life when that happens.

37:55Too early to comment on that beyond it. But you actually hit on a really key point, a really important reason why folks partner with us from the littlest to the largest. We are and really genuinely are the right party to ask, hey, should I buy this thing? Not just should I borrow this money, but should I buy this thing, service, whatever? because we are very honest when we tell you yes and here's the rate or no. We think you're overextended. We won't charge you late fees. We won't screw you. We won't kick you when you're down if you can't make a payment. We're on your side. So when we tell you no, it's a genuine compassion that you probably are overextending yourself.

38:31It is much easier to outsource that to someone like us who will not charge late fees, will treat the customer right, than trying to do it yourself. And so we are the responsible lender. Letting them down easy in some cases. I do want to ask you about interest rate. Big Fed meeting next week. What would lower rates mean for a firm's profitability going forward? Better growth. Our margin target is 3 % to 4%. We delivered on that, have been delivering on that for a very long time, intend to deliver on that. That's the cornerstone of our profitability promises. But whenever, over time, not immediately, the Fed rate cuts trickle into our cost of capital, it will allow us to approve that marginal consumer where we would have otherwise said, you know what, we can't afford the risk.

39:12The profitability picture has looked a lot better for a firm as well, as you reported in earnings. I do want to ask about politics. You know, you are a founder of PayPal. Some of your colleagues recently, or from the PayPal era at least, have sort of switched sides when it comes to their presidential bid or their party. Does this represent, in your mind, a broader shift to the right in tech in Silicon Valley? God, I'm sad. I'm very far from politics. Couldn't opine on that. Yeah, the pining and the politics sliced by Silicon Valley, that's well beyond my... I'm very busy trying to lend money to help folks buy bicycles and couches.

39:46I think we serve both the red states and the blue states and intend to do so independent of who wins and including folks in Silicon Valley. Any big policies that would impact a firm's business that you're watching for November? Yeah, I was very excited about the attack on late fees. I really do think it's a bad thing, and I'm glad CFPB and other regulators are taking a hard look at it. And, you know, it's being challenged, of course, as you might expect. But I think late fees should be at the very least capped and, if not, eliminated. If I have one wish to politicians listening, kill deferred interest.

40:19It is such an evil product. We rage against it, and it's less talked about than it should be, and it's just a bad thing. Well, Max, we'll have to leave it there. Thanks so much for your time. And Mel, we'll send it back over to you. All right, Kate, thanks. Kate Rooney with Max Levchin. What a stock since its last earnings. You mentioned that it was really a blowout. I mean, that was like a mic drop kind of. I mean, what an extraordinary quarter. And to get, you know, to be approaching profitability, that sort of makes them already obviously much more than a unicorn, but unusual for some of the others of that era of, I don't know, 2021 IPOs.

40:57Right, right. Kind of went berserk and money was free. It was sort of a different game. And yet they've done an extraordinary job. Well, look, they are clearly the go to in the buy now, pay later space. And the question is, you know, really gets back to the consumer because before that blowout number, Karen's right. Profitability fiscal fourth Q25 is something no one expected in a U.S. gap measurement. But if you look at how far they were down going into that print, about 40 percent year to date and how far down they are from when rates were essentially when money was free. That's the dynamic you're wrestling with, not whether Max and his team haven't built a great business with a lot of nobility attached.

41:31I don't like late fees either. But I think if the consumer is falling apart, I don't want to own the stock. Up next, final trades.

41:45Time for the final trade. Let's go around the horn. Tim. Yeah, 9-11, never forget. Cameco. Karen. Yes. Goob. Julie Geel. WMS guy. Newmont Mining. Gold still works here. And it is one of those days that, you know, we have a lot of fun here and we should have a lot of fun. But, you know, mile and a half down the street, you think about what happened 23 years ago and everybody's been affected by it. So we still think about it. And on that note, as we leave you tonight, we do want to show you some images from today's somber remembrances in Lower Manhattan on this 23rd anniversary of September 11th.

42:27America remembers and we will never forget.

42:49Thank you.

43:16their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.

From the publisher

August inflation declining to its lowest level since February 2021, but some components of CPI don’t seem to be budging. Why housing is so sticky, and how it could impact the Fed decision. Plus Summit Therapeutics surging nearly 100% this week on the back of new lung cancer treatment data. What it could mean for patients, and how it stacks up against the competition.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Sticky Areas of CPI… And Summit Therapeutics Co-CEOs On New Drug Results 9/11/24CNBC's "Fast Money" · 44 min
Listen in VO